Analysts expect further Big Pharma acquisitions of companies involved in the development of cannabinoid treatments to become commonplace as the promising results and growth potential of medical cannabis continue to attract interest.

However, while these acquisitions are expected to propel and expand cannabinoid treatment options, the overall impact of and interest in Big Pharma’s reach into the industry remains a matter of speculation.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

VIEW REPORTS

Request a free sample of this report:

“ Could the Pfizer acquisition of Arena be a sign of things to come in Big Pharma? ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ Could the Pfizer acquisition of Arena be a sign of things to come in Big Pharma? ”






      Analysts expect further Big Pharma acquisitions of companies involved in the development of cannabinoid treatments to become commonplace as the promising results and growth potential of medical cannabis continue to attract interest.

      However, while these acquisitions are expected to propel and expand cannabinoid treatment options, the overall impact of and interest in Big Pharma’s reach into the industry remains a matter of speculation.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik